United Therapeutics Corporation’s latest rating changes from various analysts


United Therapeutics Corporation’s filing revealed that its EVP & GENERAL COUNSEL MAHON PAUL A unloaded Company’s shares for reported $1.38 million on Aug 17. In the deal valued at $229.54 per share,6,000 shares were sold. As a result of this transaction, MAHON PAUL A now holds 36,599 shares worth roughly $ 8.35 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, MAHON PAUL A sold 6,000 shares, generating $1,417,470 in total proceeds. Upon selling the shares at $236.25, the EVP & GENERAL COUNSEL now owns 36,599 shares.

Before that, MAHON PAUL A sold 2,500 shares. United Therapeutics Corporation shares valued at $609,675 were divested by the EVP & GENERAL COUNSEL at a price of $243.87 per share. As a result of the transaction, MAHON PAUL A now holds 36,599 shares, worth roughly $8.35 million.

UBS initiated its United Therapeutics Corporation [UTHR] rating to a Buy in a research note published on Friday, December 06, 2022; the price target was $320. PT values the company’s stock at a premium of 28.73 to its Friday closing price.

Price Performance Review of UTHR

On Friday, United Therapeutics Corporation [NASDAQ:UTHR] saw its stock jump 1.64% to $228.05. On the same session, the stock had its day’s lowest price of $225.7401, but rose to a high of $229.49. Over the last five days, the stock has lost -0.42%. United Therapeutics Corporation shares have fallen nearly -17.99% since the year began. Nevertheless, the stocks have risen 0.63% over the past one year. While a 52-week high of $283.09 was reached on 01/06/23, a 52-week low of $201.65 was recorded on 05/30/23. SMA at 50 days reached $231.40, while 200 days put it at $240.12. A total of 0.25 million shares were traded, compared to the trading of 0.29 million shares in the previous session.

Levels Of Support And Resistance For UTHR Stock

The 24-hour chart illustrates a support level at 226.03, which if violated will result in even more drops to 224.01. On the upside, there is a resistance level at 229.78. A further resistance level may holdings at 231.51. The Relative Strength Index (RSI) on the 14-day chart is 45.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.62, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 69.60%. Stochastics %K at 19.01% indicates the stock is a buying.

How much short interest is there in United Therapeutics Corporation?

A steep rise in short interest was recorded in United Therapeutics Corporation stocks on Aug 14, 2023, growing by 0.9 million shares to a total of 1.89 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 0.99 million shares. There was a rise of 47.48%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 4.56% of the overall stock float, the days-to-cover ratio (short ratio) rose to 4.98.

United Therapeutics Corporation [UTHR] – Who Are The Largest Shareholders?

In filings from Wellington Management Co. LLP, it is revealed that the company now owns 4,688,824 shares, or roughly 10.01% of the outstanding UTHR shares. In other words, the investor’s shares have risen by 906,984 from its previous 13-F filing of 3781840.0. Additionally, The Vanguard Group, Inc. increased 0.80% of its stake after which the total value it holdings stand at $1,112,453,236, while BlackRock Fund Advisors added 6.09% of its stake to hold $1.04 billion in the firm. Over the last quarter, Avoro Capital Advisor LLC purchased 39,999 shares of United Therapeutics Corporation, while Fidelity Management & Research Co bought 44,457 shares. At present, Renaissance Technologies LLC is holding 2,187,214 shares valued at $530.88 million. SSgA Funds Management, Inc. owned 1,875,758 shares of the company at the time of its most recent 13F filing, worth $455.28 million.

According to FactSet, United Therapeutics Corporation’s share price will average $284.60 in the next year, based on opinions of analysts polled by the firm. This is up nearly 35.27 percent from its previous closing price of $224.36. Analysts expect United Therapeutics Corporation stock to reach the higher price of $375.00, while the lowest price estimate is $170.00. However, 12 analysts have rated UTHR stock as an Overweight in their predictions for 2023.


Please enter your comment!
Please enter your name here